Michael Burger, senior consultant at Point-of-Care Partners, explains that real-time benefit check lets physicians know how much a drug will cost the patient at the time they're writing the prescription, allowing them to give the patient a treatment they know they can afford.
At AMCP 2023, Michael Burger, senior consultant at Point-of-Care Partners, explained the important role real-time benefit check (RTBC) plays in the decision-making process.
What is real-time benefit check?
Real-time benefit check—also known as RTBC—is an electronic transaction, which is used to identify a patient's prescription benefit coverage and to identify what their out-of-pocket costs will be, as well as what any of the restrictions on that prescription might be, things like prior authorization. RTBC is available to the prescriber. So in the doctor's office at the point where the prescription is being written, information about what that prescription will cost the patient is available and it can be used as part of the decision making process to decide which drug to order for the patient.
How does RTBC encourage providers to consider costs when prescribing medications?
Prescription cost is something that is not especially transparent, it isn't uncommon for the patient to understand what the prescription will cost only when they get to the pharmacy counter. So sometimes that results in the patient not being able to afford the medication, or maybe being forced to pay for the medication and then not use it according to instructions. Maybe they cut a pill in half or they take it every other day.
So the idea behind RTBC is that the cost to the patient is known to the physician at the point where they're writing the prescription, so they can decide on the most cost effective drug, one that they know that the patient can afford, so that way they're sure that the patient gets on the therapy.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More